Figure 3From: Clinical development of mTOR inhibitors in breast cancerEverolimus sensitivity. Schematic representation of the sensitivity to everolimus. 4E-BP1, eIF4E binding protein 1; AKT, protein kinase B; AMPK, adenosine monophosphate-activated protein kinase; IGF1R, insulin growth factor 1-receptor; LKB1, liver kinase B1; mTOR, mammalian target of rapamycine; PI3K, phosphatidylinositol-3-kinase.Back to article page